Brain-Derived Neurotrophic Factor and Neurotrophin-4/5 Are Expressed in Breast Cancer and Can Be Targeted to Inhibit Tumor Cell Survival

Elsa Vanhecke1, Eric Adriaenssens1, Stéphanie Verbeke1, Samuel Meignan1, Emmanuelle Germain1, Nathalie Berteaux2, Victor Nurcombe3, Xuefen Le Bourhis1, and Hubert Hondermarck1

Abstract

Purpose: Given that nerve growth factor has previously been shown to be involved in breast cancer progression, we have tested here the hypothesis that the other neurotrophins (NT) are expressed and have an influence in breast tumor growth.

Experimental Design: The expression of brain-derived neurotrophic factor (BDNF), NT-3 and NT-4/5, as well as the neurotrophin receptor p75NTR, TrkB, and TrkC, was studied by RT-PCR, Western blotting, and immunohistochemistry in cell lines and tumor biopsies. The biological impacts of neurotrophins, and associated mechanisms, were analyzed in cell cultures and xenografted mice.

Results: BDNF and NT-4/5 were expressed and secreted by breast cancer cells, and the use of blocking antibodies suggested an autocrine loop mediating cell resistance to apoptosis. The corresponding tyrosine kinase receptor TrkB was only rarely observed at full length, whereas the expression of TrkB-T1, lacking the kinase domain, as well as p75NTR, were detected in all tested breast cancer cell lines and tumor biopsies. In contrast, NT-3 and TrkC were not detected. SiRNA against p75NTR and TrkB-T1 abolished the antiapoptotic effect of BDNF and NT-4/5, whereas the pharmacological inhibitors K252a and PD98059 had no effect, suggesting the involvement of p75NTR and TrkB-T1, but not kinase activities from Trks and MAPK. In xenografted mice, anti-BDNF, anti-NT-4/5, anti-p75NTR, or anti-TrkB-T1 treatments resulted in tumor growth inhibition, characterized by an increase in cell apoptosis, but with no change in proliferation.

Conclusion: BDNF and NT-4/5 contribute to breast cancer cell survival and can serve as prospective targets in attempts to inhibit tumor growth.

Introduction

The neurotrophins constitute a family of structurally and functionally related polypeptides including the prototypic nerve growth factor (NGF), as well as brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin 4/5 (NT-4/5). They are primarily known for their crucial roles in the development and maintenance of the nervous system, where they stimulate neuronal cell survival, differentiation, and plasticity (1). Neurotrophin activities are mediated through 2 classes of cell surface receptors: the Trk tyrosine kinase receptors and the neurotrophin receptor p75NTR, the latter a member of the Tumor Necrosis Factor-receptor superfamily (2). NGF preferentially binds TrkA, whereas BDNF and NT-4/5 bind TrkB; NT-3 primarily binds TrkC, but also TrkA and TrkB to a lesser extent (3). In contrast, all neurotrophins bind and activate p75NTR. Interestingly, non-neuronal cells can also respond to neurotrophins, in both healthy tissues and disease states; in addition to their involvement in neuroblastomas and glioblastomas, several studies have suggested a role for neurotrophins and their receptors in non neuronal cancers (4, 5). Indications that neurotrophins and their receptors can participate in tumorigenesis include data from Wilm’s tumors (6), medullary thyroid carcinoma (7), prostatic cancer (8, 9), melanoma (10), myeloma (11), as well as pancreatic (12, 13), ovarian (14), and hepatocellular (15) carcinomas. Nevertheless, these data appear fragmentary, and no comprehensive picture has been established for the involvement of all neurotrophin family members in a defined type of cancer.

In breast cancer, it has previously been shown that NGF is able to stimulate the proliferation and survival of breast tumor cells through the activation of TrkA and p75NTR, respectively (16–19). In addition, NGF cooperates with HER2 to activate breast cancer cell growth (20) and the anti-estrogen drug tamoxifen, which is widely used in...
Translational Relevance

The identification of new molecular markers and targets is crucial for the development of better-targeted treatments for breast cancer. To date, the effort to design such treatments have been limited by the molecular and cellular heterogeneity of breast tumors. The 2 clinically validated molecular targets currently used for this pathology, the estrogen receptors and the tyrosine kinase receptor Erb-R2, have a restricted spectrum of use; thus, the discovery of new targets in breast cancer constitutes a major objective. Here we show that brain-derived neurotrophic factor and neurotrophin-4/5 (NT-4/5) are expressed in breast tumors, promote breast cancer cell survival through p75NTR and TrkB-T1, and can be targeted to inhibit tumor growth. Thus, the assaying and targeting of these neurotrophins in breast cancer may have clinical ramifications.

breast cancer therapy, is able to inhibit the mitogenic effect of NGF (21). In addition, repression of SHP-1 phosphatase expression by p53 leads to TrkA tyrosine phosphorylation and the suppression of breast cancer cell proliferation (22). Given the TrkA and p75NTR expression in breast tumors (23–25), the demonstration that NGF is overexpressed in the majority of human breast tumors and that its inhibition results in diminished tumor growth in preclinical models, pointed to the potential value of NGF as a therapeutic target (26). With regard to the other neurotrophins, although it has previously been shown that exogenously added BDNF, NT-4/5, or NT-3 can produce antiapoptotic effects on breast cancer cells in vitro (16), no studies have systematically investigated the expression of these neurotrophins and their associated receptors in breast cancer cells or their potential subsequent impact on tumor growth.

Here, we report for the first time that BDNF and NT-4/5 are both expressed and secreted by breast cancer cells. An autocrine stimulation loop of BDNF and NT-4/5, mediated through p75NTR and TrkB-T1, a variant form of TrkB lacking the kinase domain, was found to be involved in tumor cell survival. These results indicate that BDNF and NT-4/5 directly contribute to breast cancer progression.

Materials and Methods

Materials

Cell culture reagents were purchased from BioWhittaker except fetal bovine serum (Perbio), culture medium (Cambrex), fibronectin (Falcon-Biocat), insulin, and transferrin (Sigma). The flasks and Petri dishes were obtained from Starstedt (Fisher-Scientific). Recombinant human neurotrophins, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) were from R&D Systems. Ceramide C2 was obtained from Sigma. Antibodies used for immunostaining were rabbit polyclonal anti-BDNF, anti-NT-3, anti-NT-4/5, anti-TrkA, anti-TrkB, and anti-TrkC from Santa Cruz Biotechnology, p75NTR antibody from Promega, anti-actin from Sigma, anti-phosphoTrkA, anti-Erk1/2, and anti-phosphoErk1/2 were from Cell Signaling, and secondary antibodies from Jackson laboratories. ECL reagents were obtained from Pierce Interchim. Neutralizing anti-NT-4/5 and BDNF antibodies were from R&D systems. K252a and PD98059 were obtained from Calbiochem. RNA and histological slides of breast tumor biopsies were from Clinisciences. Hoechst 33342, electrophoresis reagents, and chemicals were from Sigma, solvant from Fluka and Glycergel from Dako. DNase and Retro-Transcription reagents were from Invitrogen (Fisher-Scientific) and the Quantitect SYBR Green PCR kit, used for real-time PCR was obtained from Qiagen. Primers for BDNF, NT-3, NT-4/5, p75NTR, TrkB, TrkB-T1, TrkB-T-shc, and RPLP0 were from Eurogentec, primers for TrkC from Qiagen. Molecular weight standards were obtained from Fermentas.

Cell culture

The human breast epithelial cell lines (MCF-7, T-47D, MDA-MB-231, BT-20, and MCF-10A) and the human neural precursor cells NTERA-2 cl.D1 (NT2/D1) derived from the NT-2 teratocarcinoma were obtained from the American Type Culture Collection. The Human Mammary Epithelial cells (HMEC) were from Cambrex. MCF-7, T-47D, MDA-MB-231, BT-20, and MCF-10A, were routinely grown in monolayer cultures as described previously (17). HMEC and NT2/D1 were grown in conditions given by the supplier. To obtain conditioned media, MCF-7, MDA-MB-231, and HMEC were plated in 175 cm² flasks. When they reached confluence, they were washed and incubated in basal medium. Two hours later, the basal medium was changed and cells were further cultured for 24 hours. The medium was then collected, concentrated with column (Amicon), and stored at - 80 °C before use. To test neurotrophins activities, breast cancer cells were transfected by nucleofection (Amaxa) with siRNA against p75NTR 5'-AGUCCGCUCCUUGGACCUCUCC-3' and 5'-GGAGGAGCGCCGACGACA-3'(siRNA1 p75NTR), 5'-AGAGGGGCGCAGACACA-3' and 5'-UGUGGCUCGCCGAGCCUC-3'(siRNA2 p75NTR), 5'-ACGGCUCUGGAGGACCAGCC-3' and 5'-GGUCCCCUGCCCAGGAGC-3'(siRNA3 p75NTR), or control siRNA 5'-GCUUGACCUCUGAAGUUCAC-3' and 5'-GAUGAACCUCUGGACGAGC-3'(siControl), or TrkB-T1 5'-GGCCUGUUGGGUGGGAGGGG-3' and 5'-CGGACCAGCAGAGGGG-3'(siRNA1 TrkB-T1); 5'-UGGGAACUGUCUGGCUUUA-3' and 5'-UAAGCCAAUCCACCCAGGC-3'(siRNA2 TrkB-T1); 5'-GGCUCCUAUCUGUGUGGUGG-3'(siRNA3 TrkB-T1); 5'-UGCCAGCAUACUGUGACCC-3' (siRNA4 TrkB-T1); 5'-GGCCAGAUCUGUGACCC-3' (siRNA5 TrkB-T1); 5'-UCUGCCAGCAUACUGUGACCC-3'(siRNA6 TrkB-T1); 5'-UGCCAGCAUACUGUGACCC-3' (siRNA7 TrkB-T1); 5'-GGCCAGAUCUGUGACCC-3' (siRNA8 TrkB-T1). Forty-eight hours after transfection, apoptosis of breast cancer cells was induced by TRAIL, which is proapoptotic for breast cancer cells, at 5 ng/mL for 5 hours in serum-free medium. Another proapoptotic agent, the ceramide C2, was also tested at 20 μM for 24 hours. To evaluate the antiapoptotic activity of exogenous neurotrophins, we used the concentration of 200 ng/mL with or without pharmacological inhibitors: 10 nM K252a (inhibitor of Trk receptors) or 20 μM PD98059 (inhibitor of the MAP-Kinases). Antiapoptotic activity of
endogenous neurotrophins was tested using BDNF and NT-4/5 neutralizing antibodies (R&D systems) or nonrelevant antibodies as control, diluted at 1 μg/mL in serum-free medium 45 minutes before inducing apoptosis with TRAIL. For determination of apoptotic cell percentage, all cells (adherent and nonadherent) were fixed with cold methanol (−20°C) during 20 minutes and washed with phosphate-buffered saline (PBS) after staining with 1 μg/mL Hoechst 33342, for 15 minutes at room temperature in the dark. The apoptotic cells, exhibiting condensed and fragmented nuclei, were counted under a Leica fluorescence microscope in randomly selected fields. A minimum of 500–1000 cells was examined for each condition, and results were expressed as a ratio of the total number of counted cells.

**Real-time RT-PCR**

Total RNA from cells were isolated with TriReagent (Eurogenex) and RNA from cells and biopsies treated with DNase. RNA from breast tumor tissues corresponded to 1 fibroadenoma, 1 ductal carcinoma in situ, 1 adenocarcinoma, 3 invasive ductal carcinomas, 2 invasive lobular carcinomas, 1 mixed ductal and lobular carcinoma, and 1 medullary carcinoma. Reverse transcription was performed with 1 μg of RNAs, 0.5 μg of random hexamers, 200 units of Moloney murine leukemia virus reverse transcriptase for 10 min at 25°C, 50 minutes at 37°C and 15 minutes at 70°C in a final volume of 20 μL. Real-time PCR amplifications were performed using a Quantitect SYBR Green PCR kit with 2 μL of 1/10 cDNA and 500 nM of primers. The primers used were as follows: for *NT-3* transcript 5'-TGGGATCCAGGGAACCGA-CAACA-3' and 5'-CTCTGTGTGGCAGGACCTGTC-3'; *NT-4/5* 5'-AGGCAAGCAGTTGTGGATCTG-3' and 5'-GGCTGCTCGACATGGACATGTTTGCAG-3'; *BDNF* 5'-TGGCTGAGATGATTGGCTGTC-3' and 5'-CCCTATGGACATGTTTGCAG-3'; *p75NTR* 5'-ACGGGTATCCAGGATGAG-3' and 5'-AGGCCAAGCAGTCCTATGT-3'; *TrkB* full length 5'-CGGAATACGTG-3' and 5'-CGGAATACGTG-3'; *TrkB* short 5'-CTCTGTGTGGCAGGACCTGTC-3' and 5'-GGCTGCTCGACATGGACATGTTTGCAG-3'; *RPLP0* 5'-GCCAAAGATCAGGTG-3' and 5'-GCCAAAGATCAGGTG-3'; *RPLP0* C(q) for Quantitect Primer Assay. Ct of each reaction was calculated as follows: Ct corresponded to (Ct interest gene − Ct reference gene) and is added for information.

**Western blotting**

Protein extraction of subconfluent cells was performed in lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1% NP-40, 1 mM N,N,N′,N′-tetramethylxylidamine, 1 mM orthovanadate, 1% SDS, 1% protease inhibitors) at 4°C. Insoluble material was removed by centrifugation at 4°C for 15 min at 10,000 × g after proteins boiling at 95°C for 5 minutes. Total protein concentration was determined using BCA assay (Sigma). Fifty micrograms of lysates were separated on SDS-polyacrylamide gels (12.5% for NT and 7.5% for receptors), transferred onto a nitrocellulose membrane (0.45μm) (Scheilcher & Shuell) in transfer buffer [48 mM Tris-Base, 39 mM glycin, 0.0375% SDS, 20% (v/v) methanol] and blocked for 2 hours at room temperature in Tween-buffered saline with Tween-20 (TBS-T) (20 mM Tris-HCl pH 7.5, 150 mM NaCl, and 0.1% Tween-20), 5% BSA or skimmed milk. Incubation with primary antibodies was performed in blocking buffer overnight at 4°C. After washing with TBS-T, the membranes were incubated with anti-rabbit IgG peroxidase antibody (Jackson laboratories 1:10000) for 1 hour at room temperature. The reaction was revealed using the chemiluminescence kit West Pico chemiluminescent substrate (Pierce) and Hyperfilm (Amer sham Biosciences).

**Breast tumor immunohistochemistry**

Analysis of tumor biopsies was performed using tissue arrays (SuperBiochips, Clinscience), with TSA biotin system kit (PerkinElmer), according to the manufacturer's instructions. Anti-neurotrophins and anti-TrkB rabbit polyclonal antibodies (Santa Cruz) were used at dilution 1/200 in blocking buffer, overnight at 4°C, in a moist chamber. After several washes, slides were incubated for 1 hour with a secondary biotinylated goat anti-rabbit antibody (BD Pharmingen) at a final dilution of 1/2000 in blocking buffer at 37°C. After revelation of immunolabeling, sections were counterstained with hematoxylin to contrast cell nuclei and slides were then cover slipped and observed using a Leica light microscope. Photomicrographs were taken with a phase-contrast microscope connected to an Olympus optical Camedia digital camera. Negative controls were obtained by exclusion of the primary antibodies.

**Tumor xenograft growth in immunodeficient mice**

Six-week-old female severe combined immunodeficient (SCID) mice were purchased from Charles River Laboratories and acclimatized for at least 2 weeks. Mice were maintained under a 12 hours light/dark cycle at a temperature of 20°C to 22°C. Food and water were available ad libitum. Mice were maintained in accordance with the Institutional Animal Care and Use Committee procedures and guidelines. MDA-MB-231 cells were harvested and resuspended in PBS before subcutaneous injection into flanks (4 × 10⁶ cells per flank) of the animals. Three days after cell injection, anti-NT-4/5 and anti-BDNF treatments were examined for each condition, and results were expressed as a ratio of the total number of counted cells.
were applied every 3 days. 12.5 µg of antibodies (BDNF: Mab 258; NT-4/5: AF-268-NA from R&D Systems) were injected as close as possible to the tumor. For receptor inhibition, as there is no blocking antibodies against TrkB-T1, we have used a siRNA based approach. One hundred microliters of a buffer at 50 µM of siRNA against p75NTR and TrkB-T1 were used for each injection and the experiment was performed in the same experimental conditions as for the inhibition of BDNF and NT-4/5. siRNA control were also injected. The tumor volume was determined every 3 days by measuring the length (l) and width (w) and then calculating the volume as \( \pi/6 \times l \times w \times (l + w)/2 \). Eight animals were used in each group. For determination of index labeling, anti-PCNA (Pharmingen) was used for the determination of proliferating cells, and cell apoptosis was measured using terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL, Roche).

Statistics
Data are presented as mean ± standard error of the mean (SD). Statistical significance between 2 groups was evaluated using Student's t test. Asterisks and symbols in figures indicate significant difference between the test group and the control group, according to time points or conditions.

Results
Expression of neurotrophins and their receptors in breast cancer cells
The expression of BDNF, NT-3, NT-4/5, TrkB full length (TrkB-FL), TrkB-T1, TrkB-T-shc, TrkC, and p75NTR was examined in the breast cancer cell lines MDA-MB-231, MCF-7, T-47D, BT-20 as well as in the noncancerous breast epithelial cell lines MCF-10A and HMEC, using both real-time RT-PCR and immunoblotting. The results (Fig. 1) indicated that these cell lines expressed both BDNF and NT-4/5 transcripts, visualized at 200 pb and 164 pb, respectively, after RT-PCR (Fig. 1A). All breast epithelial cells, except MCF-10A, expressed the neurotrophin receptor p75NTR, whereas TrkB-FL was found only in a few samples. BDNF was detected in 6/10 tumors. We then determined the relative expression levels of BDNF, NT-4/5, p75NTR, and TrkB-T1 in these biopsies. The corresponding mRNA levels were very variable, confirming the previously noted molecular heterogeneity among mammary tumors (Fig. 2B). To study the cellular distribution of BDNF and NT-4/5, breast tissue arrays were analyzed by immunohistochemistry. Figure 3 summarizes the results obtained with the different spots of tissue for each tumor. The staining intensities for NT-4/5, BDNF, and TrkB-T1 were concentrated in and around the cancerous cells and were slightly elevated in cancer biopsies compared with normal tissues, whatever the breast cancer type. The distribution/quantification of p75NTR was not shown here, as it has been reported previously (24, 25). The levels of NT-4/5 and BDNF were estimated by microscopic observation, and breast tissues were classified into 4 different categories depending on the intensity of labeling. However, the results show no apparent relationship between the levels of BDNF, NT-4/5, and TrkB irrespective of stage, node invasion, estrogen, or progesterone receptors and p53 levels, suggesting no correlation with classical clinicopathological factors (data not shown). Together, these data demonstrate that BDNF, NT-4/5, and TrkB-T1 are expressed in breast tumors.

Biological impact of BDNF and NT-4/5 in breast cancer cells
As BDNF and NT-4/5 were found expressed in breast cancer cells, we next tested their effect on cell survival, proliferation, and migration. Our data indicated no effect of exogenously added neurotrophins on breast cancer cell proliferation and migration (data not shown), whereas an antiapoptotic effect was observed, confirming previous data (16). The 2 exogenously added neurotrophins exhibited a rescue effect on TRAIL-treated MCF-7 cells (Fig. 4A). MDA-MB-231 cells and HMEC cells were also tested, as well as the proapoptotic ceramide C2, and the same prosurvival effect of BDNF and NT-4/5 was obtained (data not shown). Therefore, the antiapoptotic effect of BDNF and NT-4/5 is not specific of TRAIL, as illustrated with the ceramide C2, which induces apoptosis in breast cancer cells through a completely different mechanism of action. In contrast, no significant antiapoptotic effects of

BDNF, NT-4/5, and associated receptors in breast tumors
Expression of BDNF, NT-4/5, and associated receptors was detected by real-time RT-PCR in a pilot series of 10 breast tumor biopsies, with a series of 45 breast tumors also being analyzed by immunohistochemistry. The RT-PCR results (Fig. 2A) show that NT-4/5, TrkB-T1, and p75NTR transcripts were present in all biopsies studied, whereas TrkB-FL was found only in a few samples. BDNF was detected in 6/10 tumors. We then determined the relative expression levels of BDNF, NT-4/5, p75NTR, and TrkB-T1 in these biopsies. The corresponding mRNA levels were very variable, confirming the previously noted molecular heterogeneity among mammary tumors (Fig. 2B). To study the cellular distribution of BDNF and NT-4/5, breast tissue arrays were analyzed by immunohistochemistry. Figure 3 summarizes the results obtained with the different spots of tissue for each tumor. The staining intensities for NT-4/5, BDNF, and TrkB-T1 were concentrated in and around the cancerous cells and were slightly elevated in cancer biopsies compared with normal tissues, whatever the breast cancer type. The distribution/quantification of p75NTR was not shown here, as it has been reported previously (24, 25). The levels of NT-4/5 and BDNF were estimated by microscopic observation, and breast tissues were classified into 4 different categories depending on the intensity of labeling. However, the results show no apparent relationship between the levels of BDNF, NT-4/5, and TrkB irrespective of stage, node invasion, estrogen, or progesterone receptors and p53 levels, suggesting no correlation with classical clinicopathological factors (data not shown). Together, these data demonstrate that BDNF, NT-4/5, and TrkB-T1 are expressed in breast tumors.
Figure 1. Expression of neurotrophins and their receptors in breast cancer cells in vitro. A, total RNA from breast cancer cell lines (MDA-MB-231, MCF-7, T-47D, BT-20) and noncancerous breast epithelial cells (MCF-10A and HMEC), plus the neuronal NT2/D1 cells as control, were isolated and reverse-transcribed. Real-time PCR amplifications of BDNF, NT-3, NT-4/5, p75NTR, TrkB-FL, TrkB-T1, TrkC, and RPLP0 as loading control, were migrated in 2% agarose gel. B, mRNA relative quantification for BDNF, NT-3, NT-4/5, p75NTR, TrkB-FL, and TrkB-T1 in breast cancer cells were calculated as explained in Materials and Methods. The ΔCt are indicated. The control represents value obtained for the NT2/D1 cells. The histogram for TrkC was not presented here because its expression was not found in any cell type. C, protein extracts of various cells were processed for Western blotting using antineurotrophins (anti-BDNF, anti-NT-3, anti-NT4/5) and antireceptors (anti-p75NTR, anti-TrkB, anti-TrkC) antibodies. Recombinant proteins or NT2/D1 cells served as positive control and an antiaxiatin antibody was used for equiloding control. D, secretion of BDNF and NT-4/5 by breast epithelial cells. Immunoblotting of conditioned media from MDA-MB-231, MCF-7 cells, and HMEC was performed using anti-BDNF and anti-NT-4/5 antibodies, recombinant BDNF and NT-4/5 proteins were used as control.
BDNF and NT-4/5 were observed with MCF-10A cells (data not shown). Interestingly, siRNA against p75NTR or TrkB-T1 abolished the NT-4/5 and BDNF antiapoptotic effect (Fig. 4A and B). For each receptor, 3 sequences of siRNA were tested and they all exhibited a similar inhibitory effect. siRNA against p75NTR and TrkB-T1 even increased the apoptosis rate compared with siRNA control. Moreover, the Trk pharmacological inhibitors K252a and the MEK inhibitor PD98059 had no impact on the BDNF and NT-4/5 survival effect, indicating the

Figure 2. Expression of neurotrophins and their receptors in breast tumors. A, total RNA from 10 breast tumors were reverse-transcribed as described in "Materials and Methods." Real-time PCR amplifications of BDNF, NT-4/5, p75NTR, TrkB-FL, TrkB-T1, and RPLP0 as loading control, were migrated in 2% agarose gel. B, relative quantification of neurotrophins and receptors mRNA expression in breast tumors. The ΔCt are indicated.
noninvolvement of either the Trk receptor tyrosine kinase or the MAP kinase pathway. The controls of siRNA and pharmacological inhibitors efficacy are shown in Figure 4C. We then tested the effect of endogenously produced NT-4/5 and BDNF on breast cancer cell growth, through a strategy of inhibition utilizing blocking antibodies. In the absence of exogenously added neurotrophins, the addition of neutralizing anti-NT-4/5 or anti-BDNF resulted in the inhibition of cell survival (Fig. 4D). In the same experimental conditions, antibodies against NT-3 had no effect (data not shown). These data strongly suggest an autocrine loop of BDNF and NT-4/5 resulting in the breast cancer cell survival. This hypothesis was confirmed in vivo, with the highly tumorigenic breast cancer cells MDA-MB-231 which were xenografted in SCID mice. The results indicated that treatments with anti-NT-4/5 or anti-BDNF induced an inhibition of tumor growth, resulting in a decrease of final tumor size (Fig. 5A and B). In addition, the proliferative and apoptotic rates in tumors were assessed by immunohistochemistry with anti-PCNA antibodies and TUNEL staining respectively (Fig. 5C), and the number of brown TUNEL- or PCNA-labeled nuclei counted in each condition. The results, synthesized in Figure 5D, revealed an increase of cell apoptosis in tumor treated with antibodies against neurotrophins, whereas no significant modification of proliferation was observed. In addition, injection of siRNA against p75NTR and TrkB-T1 also resulted in an inhibition of...
tumor growth (Fig. 5E), confirming the in vitro data. Together, these data indicate that BDNF and NT-4/5 stimulate breast tumor cell survival and resistance to apoptosis, through p75NTR and TrkB-T1, hence promoting tumor development.

Discussion

BDNF and NT-4/5 were first described for their neurotrophic properties, as they contribute to the development and maintenance of neurons in both central and peripheral nervous systems. They are generally produced by the postsynaptic targets of innervation, allowing nerve fibers to be attracted into and thus for the neuronal cell bodies to survive and establish connections into specific organs and tissues. Our results show for the first time that BDNF and NT-4/5 are also expressed and secreted by cancerous breast epithelial cells, with a widespread expression among both cell lines and tumor biopsies. Unlike NGF, which is overexpressed...
only in breast cancer cells (17), our results show that NT-4/5 and BDNF are also synthesized and secreted in significant amounts by normal breast epithelial cells, and thus they cannot be pursued as new biomarkers for breast cancer diagnosis. Considering the levels of immunoreactivity in tumor biopsies, and the strong staining observed in breast metastatic (lymph node) tissue, they may well be related to the degree of tumor

![Figure 5](http://example.com/figure5.png)

Figure 5. In vivo effect of BDNF and NT-4/5 inhibition on tumor xenograft in immunodeficient mice. A, 3 days after subcutaneous injection of MDA-MB-231 cells, SCID mice were injected with 12.5 μg of neutralizing antibodies: anti-BDNF (D), anti-NT-4/5 ( ), and nonrelevent antibodies (C) as control. Treatments were repeated every 3 days until animal sacrifice at day 40. Eight animals were used for each group and Student’s t test was performed between control groups and anti-NT-4/5 (a) and anti-BDNF (b) antibodies groups. *, P < 0.05; **, P < 0.01. The difference between control and NT-4/5 antibody-treated group was significant from day 26 (P < 0.01) through day 40 and between control and BDNF antibody treated group was significant from day 22 (P < 0.05) through days 28 to 40 (P < 0.01). Experiments were performed twice with equivalent results. The treatment was also effective if started more than 3 days after cell injection. For instance, starting the injection 3 weeks after injection produced the same inhibition of tumor growth. B, comparative tumor size differences observed after anti-BDNF or anti-NT-4/5 treatments (day 40). C and D, cell proliferation and apoptosis were measured by immunohistochemistry against PCNA and TUNEL analysis, respectively. Photographic illustrations of xenografted tumors immunohistochemistry after PCNA and TUNEL analysis are presented in C. Evaluations of cell proliferation (PCNA labeling) and apoptosis (TUNEL) from xenograft tumors are in D. Three different microscopic fields for each slide, with 3 slides for each tumor, were counted. **, P < 0.01. E, effect of siRNA against p75NTR and TrkB-T1 on xenografted MDA-MB-231 cells. The experiment was performed in the same conditions as described in A, with injection of 100 μL of a buffer at 50 μM siRNA against p75NTR (siRNA1, D), TrkB-T1 (siRNA3, ), or control siRNA (C). Eight animals were used for each group and Student’s t test was performed between control group and siRNA p75NTR (a) or siRNA TrkB-T1 (b) groups. *, P < 0.05; **, P < 0.01.
aggressiveness, albeit we have not as yet established any relationship with the known prognostic factors. Therefore, although a direct prognostic value was not shown here, we have nonetheless established that BDNF and NT-4/5 expression occurs in breast tumors.

In contrast to BDNF and NT-4/5, the corresponding tyrosine kinase receptor TrkB-FL was rarely detected, and only at low levels. The involvement of TrkB in neuronal and nonneuronal cancers has been documented, with TrkB being overexpressed in some cancers (neuroblastoma, prostate adenocarcinoma, Wilm’s tumors, pancreatic adenocarcinoma, myeloma), resulting in an increased resistance to chemotherapy, and eventually a promotion of tumor invasion, proliferation, and neuroangiogenesis (27). However, for breast cancer, this study establishes that there is only a limited expression of TrkB-FL, which was observed in only 1/4 cell lines and 2/10 breast tumors. Expression of TrkB has been reported in mouse and human breast tumors (28, 29), but although these studies did not distinguish the alternative forms of TrkB, they also reported, through Western blotting, the truncated form of TrkB at higher levels of expression than TrkB-FL itself. This prompted us to look for the expression of alternative forms of TrkB. PCR assays were designed to specifically detect TrkB-FL, TrkB-T1, and TrkB-shc. The results showed that TrkB-shc was not expressed, albeit in contrast, we detected TrkB-T1 in all tested breast cancer samples. The other receptor for BDNF and NT-4/5, p75NTR, has already been shown to be expressed in breast tumors, and has been shown to have prognostic value (23–25). Supporting this, we confirm here the expression of p75NTR in all breast cancer cell lines and tumors.

Several neurotrophic factors and receptors are involved in carcinogenesis (4). In neuroblastoma, the TrkAIII splice variant is able to act as a stimulator, and the BDNF/TrkB axis enhances not only neuroblastoma cell survival, but also resistance to chemotherapy and tumor progression (30–32). In breast cancer, the expression of NGF and glial cell-derived neurotrophic factor (GDNF) increases proliferation, survival, and breast cancer cell scattering (26, 33). Here we show that BDNF and NT-4/5 stimulation could rescue breast cancer cells from apoptosis via p75NTR and TrkB-T1, and that they can therefore be considered as prosurvival factors. The pharmacological inhibitors of Trk and MEK had no influence over the BDNF and NT-4/5 prosurvival effect, reinforcing the idea that Trk kinase activities are not involved in BDNF and NT-4/5 signaling in breast cancer cells.

The p75NTR receptor regulates neuronal cell apoptosis/survival balance (34) and binds all neurotrophins with the same affinity. In carcinogenesis, p75NTR plays complicated roles, as it is on one hand involved in the development of melanoma, through its ability to increase cell invasion, survival, and brain metastasis (35, 10) and yet, on the other hand, it acts as a growth inhibitor in prostate, gastric, and hepatocarcinomas (36–38). In this study, the inhibition of p75NTR or TrkB-T1, with specific siRNAs, abolished the BDNF and NT-4/5 antiapoptotic/prosurvival effect. Abolition of p75NTR or TrkB-T1 further increased the basal level of TRAIL-induced apoptosis, suggesting an endogenous stimulation of p75NTR and TrkB-T1 through BDNF and NT-4/5 secretion. To date, the biological role of TrkB-T1 has remained elusive. It has been hitherto described exclusively for the nervous system, where its overexpression in vitro has been reported to inhibit TrkB-FL and modulate p75NTR, leading to neuronal precursor proliferation and differentiation (39–41). Nevertheless, its mechanism of action/intracellular signaling remains unknown. Our data extend the current knowledge about TrkB-T1 by reporting its expression outside the nervous system, it also being the first time that TrkB-T1 involvement is reported for cancer. In addition, we demonstrated that TrkB-T1 is capable of stimulating breast cancer cell resistance to apoptosis, and although its precise mechanism of action has yet to be defined, our data point to a similar effect of inhibiting either TrkB-T1 or p75NTR. The hypothesis of BDNF- and NT4/5-mediated autocrine loops was sustained by our in vitro experiments, with tumor cell xenograft in immunodeficient mice, wherein blocking anti-BDNF and anti-NT-4/5 antibodies were able to decrease tumor growth. Interestingly, immunohistochemical analysis revealed that anti-BDNF or anti-NT-4/5 treatments induced increase in tumor cell apoptosis, with no effect on the rates of cell proliferation. Therefore, both the in vitro and in vivo experiments contributed to the evidence for the positive impact of BDNF and NT-4/5 on breast cancer cell apoptotic resistance. Regarding cell signaling involved it was shown, in breast cancer, that p75NTR activates NF-KB (18) via a mechanism involving BEX2 (19). Interestingly NF-KB and BEX family members are also described for p75NTR signaling in neuronal cells (42). In contrast, little is known about TrkB-T1 and in the few studies that have investigated its mechanism of action, a dominant negative function against TrkB has been proposed. Nevertheless, a role of TrkB-T1 in cell survival has already been reported as it has been shown to rescue neuronal cell death by restoring Ca2+ and restoring BDNF-induced intracellular signaling mediated by full-length TrkB (43). In addition, a very recent study (44) indicates cooperation between p75NTR and TrkB-T1 in modulating plasticity in hippocampal neurons. In our study, we found that the inhibition of p75NTR or TrkB-T1 both resulted in a complete inhibition of BDNF and NT-4/5 antiapoptotic effect, suggesting a cooperation between p75NTR and TrkB-T1 or a cross-linking of their signaling systems; however, further mechanistic investigations will be necessary to solve this question.

In conclusion, our study reveals that BDNF and NT-4/5 are involved in breast cancer. The stimulation of a resistance to apoptosis by BDNF and NT-4/5, through p75NTR and TrkB-T1, suggests their potential value as therapeutic
targets in breast cancer that offer new directions for the design of innovative strategies based on neurotrophin inhibition.

Disclosure of Potential Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgments

We thank Isabelle Pollet-Lefebvre and Nathalie Ziental-Gelas for excellent technical assistance.

References


Grant Support

This study was supported by grants from the Institut National de la Sante et de la Recherche Medicale, la Ligue Nationale Contre le Cancer (Equipe Labellisee 2009), the Ministere de l’Enseignement Superieur et de la Recherche et la Region Nord/Pass-de-Calais. E. Vanhecke was the recipient of a fellowship from the Association pour la Recherche sur le Cancer (ARC).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 16, 2010; revised December 17, 2010; accepted February 1, 2011; published OnlineFirst February 24, 2011.


Brain-Derived Neurotrophic Factor and Neurotrophin-4/5 Are Expressed in Breast Cancer and Can Be Targeted to Inhibit Tumor Cell Survival

Elsa Vanhecke, Eric Adriaenssens, Stéphanie Verbeke, et al.

Clin Cancer Res 2011;17:1741-1752. Published OnlineFirst February 24, 2011.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-10-1890

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2011/03/30/1078-0432.CCR-10-1890.DC1

Cited articles
This article cites 43 articles, 17 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/17/7/1741.full#ref-list-1

Citing articles
This article has been cited by 8 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/17/7/1741.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://clincancerres.aacrjournals.org/content/17/7/1741. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.